All In Biotech

Drug Trial Radar · NCT00359281

Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

A Phase II, Fixed-sequenced, Open- Label, Research Study to Assess Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Therapies in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Feb 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

125

Actual

Start

Mar 2006

Primary completion

Nov 2007

Study completion Nov 2007

Sponsor

Lead sponsor
Aegerion Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Aug 2, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase II, open-label research study was conducted in 129 healthy volunteers. Each subject will be given one initial oral dose of one of 7 FDA-approved medications (probe drugs), followed by a 7 day period where subjects receive the study medication AEGR-733 at 10 or 60 mg. On study day 8 subjects will receive the second oral dose of the same probe drug that was given on day 1 and a last dose of AEGR-733 (total of 7 doses).Subjects will return in 1 week for a final safety visit. Each FDA- approved probe drug will be given to ten (10) or fifteen (15) subjects. Safety, pharmacokinetic and pharmacodynamic assessments will be performed.

Conditions

  • Healthy

Interventions

  • atorvastatinDrug

    Atrovastatin 20 mg and AEGR-733 10 mg or 60 mg

  • simvastatinDrug

    Simvastatin 20 mg and AEGR-733 10 mg or 60 mg

  • ezetimibeDrug

    Ezetimibe 10 mg and AEGR-733 10 mg

  • fenofibrateDrug

    Micronized Fenofibrate 145 mg and AEGR-733 10 mg

  • dextromethorphanDrug

    Dextromethorphan 30 mg and AEGR-733 10 mg

  • Extended Release NiacinDrug

    1000 mg ER niacin and AEGR-733 10 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under Concentration-time Curve From 0 to Last Measureable Concentration (AUC0-t) Atorvastatin Acid (Lomitapide 10 mg)Time frame: 0 to 24 hour
  2. AUC0-t SimvastatinTime frame: 0 to 24 hours
  3. AUC0-t Simvastatin AcidTime frame: 0 to 24 hours
  4. AUC0-t Total EzetimibeTime frame: 0 to 24 hours
  5. AUC0-t Rosuvastatin (Lomitapide 10 mg)Time frame: 0 to 24 hours
  6. AUC0-t Fenofibric AcidTime frame: 0 to 24 hours
  7. AUC0-t Atorvastatin Acid (Lomitapide 60 mg)Time frame: 0 to 24 hours
  8. AUC0-t Rosuvastatin (Lomitapide 60 mg)Time frame: 0 to 24 hours
  9. AUC0-t Nicotinic AcidTime frame: 0 to 24 hours
  10. AUC0-t Nicotinuric AcidTime frame: 0 to 24 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Pennsylvania

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.